New Launch10 Dec 2025, 04:12 pm
Cipla Launches Yurpeak® (Tirzepatide) in India for Obesity and Type 2 Diabetes Treatment
AI Summary
Cipla Limited has announced the launch of Yurpeak® (tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes mellitus. The company has the rights to distribute and promote Yurpeak® under a marketing and distribution agreement with Eli Lilly and Company (India) Private Limited. The therapy will be available in six strengths and will be complemented with comprehensive patient education and support programs.
Key Highlights
- Cipla launches Yurpeak® (tirzepatide) for the treatment of Obesity and Type 2 Diabetes
- Yurpeak® will be available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths
- Cipla has the rights to distribute and promote Yurpeak® in India
- Launch of Yurpeak® will help expand access to tirzepatide in India
- Cipla will complement the launch with comprehensive patient education and support programs